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aimed to assess the long-term clinical and angiographic impact of SF
on Xience everolimus-eluting stent (EES) and Nobori biolimus-eluting
stent (BES) implantation.
METHODS From 2010 to 2013, 3246 lesions (1783 patients) were
treated with EES and 1618 lesions (986 patients) with BES, in which
follow-up angiography was performed within one year after index
procedure. SF was deﬁned as the separation of stent segments or stent
struts at follow-up angiography. The mid-term angiography was per-
formed at 8 months and the late-term at 20 months. ISR was deﬁned
as more than 50% restenosis. Late catch-up phenomenon was deﬁned
as ISR, excluding that within one year after index procedure.
RESULTS SF was observed in 1.7% (56/3246) of the lesions treated
with EES and 4.4% (72/1618) with BES. The median follow-up duration
of the study population was 1028 days (the ﬁrst and third quarters,
838 and 1275 days). The mid-term restenosis rate showed no signiﬁ-
cant difference between the EES and BES groups (40.7% versus 30.6%,
p¼0.26). The late catch-up phenomenon rate was signiﬁcantly lower
in the BES group (18.2% versus 2.4%, p¼0.04). Very late stent
thrombosis was none in the EES group, on the other hand, occurred in
one patient in the BES group. The three-year cumulative rates of any
TLR did not signiﬁcantly differ between the 2 groups (44.8% versus
29.7%, p¼0.07). A landmark analysis of the cumulative rates of any
TLR within and beyond one year is shown in the ﬁgure.
CONCLUSIONS The long-term clinical impact of SF could be different
between EES and BES implantation.
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BACKGROUND In second generation DES era, in-stent restenosis (ISR)
is not commonly seen but is still encountered occasionally. The
pathophysiology and mechanism of ISR after second generation DES
implantation have not been fully clariﬁed.
METHODS Patients who underwent follow-up coronary angio-
graphy (CAG) after ﬁrst (Cypher and Taxus) and second generationDES (Nobori, Promus Element, Resolute Integrity, and Xience) im-
plantation were examined. The ﬁrst scheduled CAG was performed at
six to nine months after percutaneous coronary intervention (PCI) and
the second at 18 to 24 months after PCI. ISR was deﬁned as lesions
more than 75% diameter stenosis at follow-up CAG. Optical coherence
tomography (OCT) was performed at the time of revascularization to
ISR. Then OCT imaging of second generation DES ISR of early (<1 year)
and late ( 1 year) phase were compared with ﬁrst generation DES ISR,
retrospectively.
RESULTS From April 2008 to January 2010, ﬁrst generation DES were
implanted in 805 lesions. From January 2011 to December 2014, sec-
ond generation DES were implanted in 1269 lesions in our hospital.
ISR rate were signiﬁcantly lower in second generation DES ISR (9.6%
(N¼77) vs 4.0% (N¼51), p<0.05). In qualitative OCT assessment of
second generation DES ISR in total, each ratio of homogeneous,
layered, heterogeneous, lipid rich attenuation, calciﬁed nodule tissue
morphologies were 54.0% and 16.2%, 18.9%, 5.4%, and 5.4% respec-
tively. Compared with ﬁrst generation DES ISR, both in early and late
ISR cases, homogeneous morphology was signiﬁcantly higher in sec-
ond generation DES ISR (61.1% vs 36.0%, and 47.3% vs 8.0%,
respectively, p<0.05).
CONCLUSIONS Homogeneous tissue morphology assessed by OCT
was more frequently found in second generation DES ISR than ﬁrst
generation DES ISR, especially in early phase (<1 year). This ﬁnding
suggests that neointimal hyperplasia is main mechanism in second
generation DES early ISR and arterial healing process is smooth like
bare metal stents implantation.
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BACKGROUND The thin-strut, everolimus-eluting, platinum chro-
mium PROMUS Element stent (Boston Scientiﬁc, Marlborough MA)
has shown favorable early outcomes up to 4 years post-implantation
for the treatment of de novo long lesions or lesions in small-caliber
vessels, but long-term follow-up has not been previously reported.
METHODS PLATINUM SV and LL are prospective, single-arm, multi-
national studies that enrolled patients with angina pectoris or docu-
mented silent ischemia and a single de novo native coronary artery
target lesion. PLATINUM SV enrolled 94 subjects with baseline vessel
diameter 2.25 mm to <2.50 mm and lesion length 28 mm, and
PLATINUM LL enrolled 102 patients with a target lesion >24
to 34 mm long with vessel diameter 2.50 to 4.25 mm. Follow-up
was performed for 5 years.
RESULTS Patients were predominantly male (SV: 72.3%, LL: 62.7%)
and approximately one third had diabetes (SV: 42.6%, LL: 30.0%). The
mean baseline reference vessel diameter (RVD) in SV was 2.0  0.3 mm
and lesion length was 14.2  7.0 mm. For the LL study, RVD was 2.6 
0.4 and mean lesion length was 24.4  8.2 mm. The primary endpoint,
1-year target lesion failure (TLF,; cardiac death, myocardial infarction
(MI) related to the target vessel, ischemia-driven target lesion revas-
cularization [TLR]), was 2.4% for SV and 3.2% for LL, both signiﬁcantly
less than prespeciﬁed performance goals (P<0.001 for each). At 5 years,
TLF, TLR, cardiac death, MI and ARC stent thrombosis (ST) had
occurred in 6 (7.0%), 3 (3.6%), 5 (5.9%), 2 (2.4%), and 0 (0%) patients
respectively in the SV trial and TLF, TLR, cardiac death, MI and ARC
stent thrombosis (ST) had occurred in 13 (13.6%), 7 (7.5%), 5 (5.9%), 1
(1.3%), and 0 (0%) patients respectively in the LL trial.
